

APTUS PHARMA LIMITED

Date: 28.04.2026

To,
The BSE Ltd
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400001

Security Code: 544529

Scrip ID: APPL

Subject: Submission of Press Release on Financial Results pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release issued by the Company in connection with the Financial Results for the half year and year ended on 31st March, 2026, approved by the Board of Directors at its meeting held on 27th April, 2026.

The same is also being made available on the website of the Company.

Kindly take the same on your record and oblige.

Thanking you,

**Yours faithfully,
For Aptus Pharma Limited**

Hathi Tejash
Maheshchandra


Digitally signed by Hathi Tejash
Maheshchandra
Date: 2026.04.28 19:44:24 +05'30'

**Tejash Hathi
Managing Director
DIN: 03151221**

Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM



Aptus Pharma Limited

Connecting.....Life



www.aplus-pharma.com | info@aptuspharma.com | export@aptuspharma.com | +91 76004 27827

PRESS RELEASE

BSE SME Listed Aptus Pharma Limited Doubles Revenue, Builds 250+ Product Portfolio, and Accelerates Multi-Vertical Expansion

In a strong phase of growth and execution, Aptus Pharma Limited has delivered a standout performance with revenue doubling and a robust increase in net profit, reflecting both scale and operational strength.

Key Standalone Financial Highlights (Rs. In Lakhs)

Particulars	Standalone Financials		
	FY26	FY25	YoY%
Total Revenue	4,670.81	2,463.64	89.59%
EBIDTA	750.32	475.70	57.73%
EBIDTA Margin	16.06%	19.31%	
PAT	461.99	309.96	49.05%
PAT Margin	9.89%	12.58%	

Established in 2010, the company has evolved into a fast-growing pharmaceutical player focused on brand building, product expansion, and market penetration. Operating on an asset-light model through WHO-GMP certified manufacturing partners, Aptus ensures quality, scalability, and capital efficiency while maintaining agility in competitive markets.

The company's product portfolio has expanded significantly to 250+ formulations across chronic, acute, and wellness segments, supported by continuous innovation and aggressive launches. Its business is strategically structured across key verticals including the Rx (prescription) segment, which drives core revenues through strong doctor engagement; the OTC vertical, focused on consumer healthcare and wellness; the Global vertical, contributing through exports and related service income; and the ORBIT division, a scalable franchise-led model accelerating market penetration and expanding reach into underpenetrated regions.

This growth is backed by a strong distribution network covering 25K+ retail outlets, supported by 200+ distributors and sub-distributors, and reinforced by the trust of 10K+ doctors, enabling deeper and sustained market penetration across multiple states.

Listed on the BSE SME platform, Aptus Pharma Limited continues to strengthen its position with a clear roadmap to achieve pan-India presence by 2030, expand its manufacturing capabilities for better margins and control, and build a global footprint through its export initiatives. With its strong distribution backbone, the company may also explore entry into the retail pharmacy chain segment, further integrating its business model.

From a local player to a fast-emerging regional force, Aptus Pharma Limited is now steadily marching toward becoming a strong national-level pharmaceutical player over the next 3–5 years, backed by scale, diversification, and sustained execution.